Results 71 to 80 of about 45,441 (213)

Bridging practices prior to brexucabtagene autoleucel for mantle cell lymphoma in the United Kingdom: An analysis of modality, response, toxicity and survival

British Journal of Haematology, EarlyView.
Summary Bridging therapy (BT) prior to brexucabtagene autoleucel (brexu‐cel) in mantle cell lymphoma (MCL) is supported by limited evidence. Here, we report BT modality and outcome in 176 patients at 15 centres in the United Kingdom. BT was delivered to 90% (158/176), the majority receiving standard chemotherapy +/− radiotherapy (53%) (SD chemo +/− RT)
Maeve A. O'Reilly, William Wilson, Bernard Maybury, Andrea Kuhnl, Claire Roddie, Ben Uttenthal, Rod Johnson, Rajesh Alajangi, Thomas Creasey, Ahmed Abdulgawad, Carlos Gonzalez Arias, Sunil Iyengar, Graeme Ferguson, Katerina Panopoulou, Alison Delaney, Angharad Pryce, Lourdes Rubio, Ceri Jones, Jonathan Lambert, Shweta Gupta, Amrith Mathew, Shenbagaram Kasivisvanathan, Olateni Awofisayo, Shreyas Hanmantgad, Graham P. Collins, Caroline Besley, Frances Seymour, Robin Sanderson, Sridhar Chaganti   +28 more
wiley   +1 more source

Characteristics of follicular and mantle cell lymphoma in Brazil: prognostic impact of clinical parameters and treatment conditions in two hospitals

Hematology, Transfusion and Cell Therapy, 2018
Objective: Follicular and mantle cell lymphoma are low-grade B-cell malignancies that lack good responses to chemoimmunotherapy. This study aimed to assess retrospectively clinicopathological features and to determine independent prognostic factors for ...
Guilherme Rossi Assis-Mendonça, André Henrique Crepaldi, Márcia Torresan Delamain, Adriana Helena Moreira, Felipe D’Almeida Costa, Vladmir Cláudio Cordeiro de Lima, Cármino Antonio de Souza, Fernando Augusto Soares, José Vassallo   +8 more
doaj   +1 more source

Vitamin D3 receptor is highly expressed in Hodgkin's lymphoma [PDF]

, 2012
Background: Hodkin s lymphoma is one of the most frequent lymphoma in western world. Despite an overall good prognosis some patients suffer relapsing tumors which are difficult to cure.
Benz, Alexander, Christoph, Renné, Hansmann, Martin L.   +2 more
core   +2 more sources

Family history of haematological malignancy and prognosis across non‐Hodgkin lymphoma subtypes

British Journal of Haematology, EarlyView.
Multivariable‐adjusted associations between family history of haematological malignancy (FHHM) and survival outcomes by non‐Hodgkin lymphoma subtype [OS (A), EFS (B), LSS (C) and failure to achieve EFS at 24 months (D)]. Subtype‐specific analyses showed that FHHM was associated with significantly inferior EFS in MCL and inferior LSS in FL.
George A. Cholack, Raphael Mwangi, Prokop Vodička, Thomas M. Habermann, Verena Hinder, Dennis P. Robinson, Andrew L. Feldman, Thomas E. Witzig, Jose C. Villasboas, Stephen M. Ansell, Brian K. Link, Yucai Wang, Carrie A. Thompson, Susan L. Slager, Matthew Maurer, Anne J. Novak, James R. Cerhan   +16 more
wiley   +1 more source

Acute dyspnoea and single tracheal localisation of mantle cell lymphoma

Journal of Hematology & Oncology, 2010
Background Mantle cell lymphoma is a lymphoid entity characterized by adenopathy, blood and bone marrow involment which only recurrent mucosal localisation is the lymphomatoid polyposis. Few other mucosal infiltrations have been already reported. Results
Quintin-Roué Isabelle, Morel Frederic, André Norbert, Eveillard Jean-Richard, Tempescul Adrian, Ianotto Jean-Christophe, Berthou Christian   +6 more
doaj   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, EarlyView.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source

“Double trouble” – synchronous mantle cell lymphoma and metastatic squamous cell carcinoma in an inguinal lymph node

Polish Journal of Pathology, 2017
Multiple primary neoplasms may also occur synchronously. Lymphoma may coexist with second malignant tumor in its primary location or malignant tumor may metastases to lymphomatous lymph nodes.
Anna Szumera-Ciećkiewicz, Barbara Bikowska-Opalach, Monika Prochorec-Sobieszek   +2 more
doaj   +1 more source

Mantle cell lymphoma negative for t(11,14) involving the kidneys: a case report

Journal of Medical Case Reports, 2022
Background Mantle cell lymphoma is the rarest subtype of non-Hodgkin’s lymphoma. It can exhibit diverse extranodal manifestations. However, renal involvement is uncommon, and if it occurs, it usually only gets detected postmortem.
Hasan Nassereldine, Razan Mohty, Hussein Awada, Iman Abou Dalle, Jean El-Cheikh, Ali Bazarbachi   +5 more
doaj   +1 more source

Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial [PDF]

, 2019
Aprospective trial conducted in the period 2000-2005 showed no survival advantage for high-dose chemotherapy with rituximab and autograft (RHDS) versus conventional chemotherapy with rituximab (CHOP-R) as firstline therapy in 134 high-risk follicular ...
Angrilli, F., Barbui, A. M., Benedetti, F., Billio, A., Boccomini, C., Bruna, R., Castellino, C., Ciceri, F., Corradini, P., Devizzi, L., Di Raimondo, F., Dondi, A., Gini, G., Gueli, A., Ladetto, M., Lanza, F., Liberati, A. M., Mantoan, B., Massimo Gianni, A., Musso, M., Narni, F., Parvis, G., Passera, R., Patti, C., Perrone, T., Pulsoni, A., Rambaldi, A., Rossini, F., Rota-Scalabrini, D., Semenzato, G., Stelitano, C., Tarella, C., Tucci, A., Zallio, F., Zoli, V.   +34 more
core   +4 more sources

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source